| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Total other (expense) income, net | -11,416 | -1,433 | 35,884 | 108,045 |
| (loss) income before taxes | -30,614 | -20,749 | 23,023 | 98,470 |
| Income tax expense (benefit) | 11 | 16 | -14 | 7 |
| Net (loss) income | -30,625 | -20,765 | 23,037 | 98,463 |
| Unrealized income on investments, net | 75 | -34 | - | - |
| Comprehensive (loss) income | -30,550 | -20,799 | - | - |
| Net (loss) income per share of common stock - basic (in dollars per share) | -2.19 | -1.92 | 0.98 | 4.21 |
| Net loss per share of common stock - diluted (in dollars per share) | -2.19 | -1.92 | -2.83 | -14.07 |
| Weighted average common shares outstanding, basic (in shares) | 14,000,451 | 10,829,760 | 5,546,257 | 1,034,130 |
| Weighted average common shares outstanding, diluted (in shares) | 14,000,451 | 10,829,760 | 10,784,037 | 7,653,302 |
Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. (AVTX)